Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Amdipharm UK Limited, Capital House, 85 King William Street, London, EC4N 7BL, UK
Maxolon Injection.
| Pharmaceutical Form |
|---|
|
Clear colourless solution for intramuscular or intravenous administration. |
Each 2ml ampoule contains Metoclopramide Hydrochloride BP equivalent to 10mg of the anhydrous substance.
Excipient(s) with known effect: Sodium Metabisulphite – 1.48mg (0.148 % w/v).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Metoclopramide |
The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastro-intestinal tract where it has the effect of encouraging normal peristaltic action. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor. |
| List of Excipients |
|---|
|
Sodium chloride |
Clear glass 2ml ampoules (Ph. Eur. Type I neutral glass) in packs of 1 or 12 ampoules or 1 ampoule plus 12 tablets in an aluminium canister as a home visit pack.
Not all pack sizes may be marketed.
Amdipharm UK Limited, Capital House, 85 King William Street, London, EC4N 7BL, UK
PL 20072/0051
16/06/1995
| Drug | Countries | |
|---|---|---|
| MAXOLON | Australia, Ireland, New Zealand, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
